Skip to main content
PMC home page
Virologica Sinica logoLink to Virologica Sinica
. 2014 Jan 17;29(1):10–16. doi: 10.1007/s12250-014-3410-5

New therapeutic vaccination strategies for the treatment of chronic hepatitis B

Jia Liu 1, Anna Kosinska 1, Mengji Lu 1, Michael Roggendorf 1,✉
PMCID: PMC8206263  PMID: 24452539

Abstract

Chronic hepatitis B virus (CHB) is currently treated with either interferon-based or nucleot(s)ide-based antiviral therapies. However, treatment with pegylated interferon alpha results in a durable antiviral response in only about 30% patients and is associated with side effects. Most patients receiving nucleot(s)ide analogue treatment do not establish long-term, durable control of infection and have rebounding viremia after cessation of therapy. Thus, novel therapy strategies are necessary to achieve the induction of potent and durable antiviral immune responses of the patients which can maintain long-term control of viral replication. Therapeutic vaccination of HBV carriers is a promising strategy for the control of hepatitis B. Here the authors review new therapeutic vaccination strategies to treat chronic hepatitis B which may be introduced for patient treatment in the future.

Keywords: hepatitis B virus, woodchuck hepatitis virus, therapeutic vaccination, immunomodulation, programmed death-1

References

  1. Barber D L, Wherry E J, Masopust D, Zhu B, Allison J P, Sharpe A H, Freeman G J, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439:682–687. doi: 10.1038/nature04444. [DOI] [PubMed] [Google Scholar]
  2. Blum H E, Gerok W, Vyas G N. The molecular biology of hepatitis B virus. Trends Genet: TIG. 1989;5:154–158. doi: 10.1016/0168-9525(89)90057-7. [DOI] [PubMed] [Google Scholar]
  3. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, Boehme R, Panebianco R, Fiaccadori F, Ferrari C. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest. 1998;102:968–975. doi: 10.1172/JCI3731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, Laccabue D, Zerbini A, Cavalli A, Missale G, Bertoletti A, Ferrari C. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol. 2007;81:4215–4225. doi: 10.1128/JVI.02844-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Boni C, Penna A, Bertoletti A, Lamonaca V, Rapti I, Missale G, Pilli M, Urbani S, Cavalli A, Cerioni S, Panebianco R, Jenkins J, Ferrari C. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol. 2003;39:595–605. doi: 10.1016/S0168-8278(03)00292-7. [DOI] [PubMed] [Google Scholar]
  6. Chisari F V, Isogawa M, Wieland S F. Pathogenesis of hepatitis B virus infection. Pathol Biol. 2010;58:258–266. doi: 10.1016/j.patbio.2009.11.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Couillin I, Pol S, Mancini M, Driss F, Brechot C, Tiollais P, Michel M L. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis. 1999;180:15–26. doi: 10.1086/314828. [DOI] [PubMed] [Google Scholar]
  8. Dahmen A, Herzog-Hauff S, Bocher W O, Galle P R, Lohr H F. Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J Med Virol. 2002;66:452–460. doi: 10.1002/jmv.2165. [DOI] [PubMed] [Google Scholar]
  9. Dandri M, Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut. 2012;61Suppl1:i6–17. doi: 10.1136/gutjnl-2012-302056. [DOI] [PubMed] [Google Scholar]
  10. Day C L, Kaufmann D E, Kiepiela P, Brown J A, Moodley E S, Reddy S, Mackey E W, Miller J D, Leslie A J, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry E J, Coovadia H M, Goulder P J, Klenerman P, Ahmed R, Freeman G J, Walker B D. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443:350–354. doi: 10.1038/nature05115. [DOI] [PubMed] [Google Scholar]
  11. Dikici B, Bosnak M, Ucmak H, Dagli A, Ece A, Haspolat K. Failure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infection. J Gastroen Hepatol. 2003;18:218–222. doi: 10.1046/j.1440-1746.2003.02950.x. [DOI] [PubMed] [Google Scholar]
  12. Fiedler M, Kosinska A, Schumann A, Brovko O, Walker A, Lu M, Johrden L, Mayer A, Wildner O, Roggendorf M. Prime/boost immunization with DNA and adenoviral vectors protects from hepatitis D virus (HDV) infection after simultaneous infection with HDV and woodchuck hepatitis virus. J Virol. 2013;87:7708–7716. doi: 10.1128/JVI.00645-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Finnefrock A C, Tang A, Li F, Freed D C, Feng M, Cox K S, Sykes K J, Guare J P, Miller M D, Olsen D B, Hazuda D J, Shiver J W, Casimiro D R, Fu T M. PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination. J Immunol. 2009;182:980–987. doi: 10.4049/jimmunol.182.2.980. [DOI] [PubMed] [Google Scholar]
  14. Freeman G J, Wherry E J, Ahmed R, Sharpe A H. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med. 2006;203:2223–2227. doi: 10.1084/jem.20061800. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ganem D, Prince A M. Hepatitis B virus infection—natural history and clinical consequences. New Engl J Med. 2004;350:1118–1129. doi: 10.1056/NEJMra031087. [DOI] [PubMed] [Google Scholar]
  16. Ha S J, Mueller S N, Wherry E J, Barber D L, Aubert R D, Sharpe A H, Freeman G J, Ahmed R. Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med. 2008;205:543–555. doi: 10.1084/jem.20071949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hervas-Stubbs S, Lasarte J J, Sarobe P, Vivas I, Condreay L, Cullen J M, Prieto J, Borras-Cuesta F. T-helper cell response to woodchuck hepatitis virus antigens after therapeutic vaccination of chronically-infected animals treated with lamivudine. J Hepatol. 2001;35:105–111. doi: 10.1016/S0168-8278(01)00063-0. [DOI] [PubMed] [Google Scholar]
  18. Horiike N, Fazle Akbar S M, Michitaka K, Joukou K, Yamamoto K, Kojima N, Hiasa Y, Abe M, Onji M. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J Clin Virol: the official publication of the Pan American Society for Clinical Virology. 2005;32:156–161. doi: 10.1016/j.jcv.2004.07.004. [DOI] [PubMed] [Google Scholar]
  19. Jung M C, Spengler U, Schraut W, Hoffmann R, Zachoval R, Eisenburg J, Eichenlaub D, Riethmuller G, Paumgartner G, Ziegler-Heitbrock H W. Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J Hepatol. 1991;13:310–317. doi: 10.1016/0168-8278(91)90074-L. [DOI] [PubMed] [Google Scholar]
  20. Jung M C, Gruner N, Zachoval R, Schraut W, Gerlach T, Diepolder H, Schirren C A, Page M, Bailey J, Birtles E, Whitehead E, Trojan J, Zeuzem S, Pape G R. Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. Vaccine. 2002;20:3598–3612. doi: 10.1016/S0264-410X(02)00309-2. [DOI] [PubMed] [Google Scholar]
  21. Kosinska A D, Johrden L, Zhang E, Fiedler M, Mayer A, Wildner O, Lu M, Roggendorf M. DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model. J Virol. 2012;86:9297–9310. doi: 10.1128/JVI.00506-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kosinska A D, Zhang E, Johrden L, Liu J, Seiz P L, Zhang X, Ma Z, Kemper T, Fiedler M, Glebe D, Wildner O, Dittmer U, Lu M, Roggendorf M. Combination of DNA prime-adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS Pathog. 2013;9:e1003391. doi: 10.1371/journal.ppat.1003391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Li F J, Zhang Y, Jin G X, Yao L, Wu D Q. Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients. Immunol Lett. 2013;150:116–122. doi: 10.1016/j.imlet.2012.12.004. [DOI] [PubMed] [Google Scholar]
  24. Liang T J. Hepatitis B: the virus and disease. Hepatology. 2009;49:S13–21. doi: 10.1002/hep.22881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Locarnini S, Mason W S. Cellular and virological mechanisms of HBV drug resistance. J Hepatol. 2006;44:422–431. doi: 10.1016/j.jhep.2005.11.036. [DOI] [PubMed] [Google Scholar]
  26. Lu M, Yao X, Xu Y, Lorenz H, Dahmen U, Chi H, Dirsch O, Kemper T, He L, Glebe D, Gerlich W H, Wen Y, Roggendorf M. Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model. J Virol. 2008;82:2598–2603. doi: 10.1128/JVI.01613-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Maier H, Isogawa M, Freeman G J, Chisari F V. PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol. 2007;178:2714–2720. doi: 10.4049/jimmunol.178.5.2714. [DOI] [PubMed] [Google Scholar]
  28. Maini M K, Boni C, Lee C K, Larrubia J R, Reignat S, Ogg G S, King A S, Herberg J, Gilson R, Alisa A, Williams R, Vergani D, Naoumov N V, Ferrari C, Bertoletti A. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med. 2000;191:1269–1280. doi: 10.1084/jem.191.8.1269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Mancini-Bourgine M, Fontaine H, Brechot C, Pol S, Michel M L. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine. 2006;24:4482–4489. doi: 10.1016/j.vaccine.2005.08.013. [DOI] [PubMed] [Google Scholar]
  30. Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Brechot C, Michel M L. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology. 2004;40:874–882. doi: 10.1002/hep.20408. [DOI] [PubMed] [Google Scholar]
  31. Menne S, Roneker C A, Tennant B C, Korba B E, Gerin J L, Cote P J. Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection. Intervirology. 2002;45:237–250. doi: 10.1159/000067914. [DOI] [PubMed] [Google Scholar]
  32. Menne S, Roneker C A, Korba B E, Gerin J L, Tennant B C, Cote P J. Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. J Virol. 2002;76:5305–5314. doi: 10.1128/JVI.76.11.5305-5314.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Paoletti E. Applications of pox virus vectors to vaccination: an update. P Natl Acad Sci USA. 1996;93:11349–11353. doi: 10.1073/pnas.93.21.11349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Penna A, Chisari F V, Bertoletti A, Missale G, Fowler P, Giuberti T, Fiaccadori F, Ferrari C. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med. 1991;174:1565–1570. doi: 10.1084/jem.174.6.1565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Penna A, Pilli M, Zerbini A, Orlandini A, Mezzadri S, Sacchelli L, Missale G, Ferrari C. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology. 2007;45:588–601. doi: 10.1002/hep.21541. [DOI] [PubMed] [Google Scholar]
  36. Perkus M E, Piccini A, Lipinskas B R, Paoletti E. Recombinant vaccinia virus: immunization against multiple pathogens. Science. 1985;229:981–984. doi: 10.1126/science.2992092. [DOI] [PubMed] [Google Scholar]
  37. Petrovas C, Casazza J P, Brenchley J M, Price D A, Gostick E, Adams W C, Precopio M L, Schacker T, Roederer M, Douek D C, Koup R A. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med. 2006;203:2281–2292. doi: 10.1084/jem.20061496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Pilli M, Zerbini A, Penna A, Orlandini A, Lukasiewicz E, Pawlotsky J M, Zeuzem S, Schalm S W, von Wagner M, Germanidis G, Lurie Y, Esteban J I, Haagmans B L, Hezode C, Lagging M, Negro F, Homburger Y, Neumann A U, Ferrari C, Missale G. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project) Gastroenterology. 2007;133:1132–1143. doi: 10.1053/j.gastro.2007.06.059. [DOI] [PubMed] [Google Scholar]
  39. Pol S, Driss F, Michel M L, Nalpas B, Berthelot P, Brechot C. Specific vaccine therapy in chronic hepatitis B infection. Lancet. 1994;344:342. doi: 10.1016/S0140-6736(94)91384-6. [DOI] [PubMed] [Google Scholar]
  40. Pol S, Nalpas B, Driss F, Michel M L, Tiollais P, Denis J, Brecho C. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol. 2001;34:917–921. doi: 10.1016/S0168-8278(01)00028-9. [DOI] [PubMed] [Google Scholar]
  41. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5:215–229. doi: 10.1038/nri1573. [DOI] [PubMed] [Google Scholar]
  42. Ren F, Hino K, Yamaguchi Y, Funatsuki K, Hayashi A, Ishiko H, Furutani M, Yamasaki T, Korenaga K, Yamashita S, Konishi T, Okita K. Cytokine-dependent anti-viral role of CD4-positive T cells in therapeutic vaccination against chronic hepatitis B viral infection. J Med Virol. 2003;71:376–384. doi: 10.1002/jmv.10509. [DOI] [PubMed] [Google Scholar]
  43. Robinson H L. New hope for an AIDS vaccine. Nature reviews. Immunology. 2002;2:239–250. doi: 10.1038/nri776. [DOI] [PubMed] [Google Scholar]
  44. Safadi R, Israeli E, Papo O, Shibolet O, Melhem A, Bloch A, Rowe M, Alper R, Klein A, Hemed N, Segol O, Thalenfeld B, Engelhardt D, Rabbani E, Ilan Y. Treatment of chronic hepatitis B virus infection via oral immune regulation toward hepatitis B virus proteins. Am J Gastroenterol. 2003;98:2505–2515. doi: 10.1111/j.1572-0241.2003.07700.x. [DOI] [PubMed] [Google Scholar]
  45. Sallberg M, Hughes J, Javadian A, Ronlov G, Hultgren C, Townsend K, Anderson C G, O’Dea J, Alfonso J, Eason R, Murthy K K, Jolly D J, Chang S M, Mento S J, Milich D, Lee W T. Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen. Hum Gene Ther. 1998;9:1719–1729. doi: 10.1089/hum.1998.9.12-1719. [DOI] [PubMed] [Google Scholar]
  46. Schurich A, Khanna P, Lopes A R, Han K J, Peppa D, Micco L, Nebbia G, Kennedy P T, Geretti A M, Dusheiko G, Maini M K. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology. 2011;53:1494–1503. doi: 10.1002/hep.24249. [DOI] [PubMed] [Google Scholar]
  47. Tatsis N, Ertl H C. Adenoviruses as vaccine vectors. Mol Ther. 2004;10:616–629. doi: 10.1016/j.ymthe.2004.07.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann K A, Purcell R H, Chisari F V. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol. 2003;77:68–76. doi: 10.1128/JVI.77.1.68-76.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Trautmann L, Janbazian L, Chomont N, Said E A, Gimmig S, Bessette B, Boulassel M R, Delwart E, Sepulveda H, Balderas R S, Routy J P, Haddad E K, Sekaly R P. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med. 2006;12:1198–1202. doi: 10.1038/nm1482. [DOI] [PubMed] [Google Scholar]
  50. Vandepapeliere P, Lau G K, Leroux-Roels G, Horsmans Y, Gane E, Tawandee T, Merican M I, Win K M, Trepo C, Cooksley G, Wettendorff M, Ferrari C. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine. 2007;25:8585–8597. doi: 10.1016/j.vaccine.2007.09.072. [DOI] [PubMed] [Google Scholar]
  51. Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L, Vanderford T H, Chennareddi L, Silvestri G, Freeman G J, Ahmed R, Amara R R. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature. 2009;458:206–210. doi: 10.1038/nature07662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Wang X Y, Zhang X X, Yao X, Jiang J H, Xie Y H, Yuan Z H, Wen Y M. Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine. Vaccine. 2010;28:8169–8174. doi: 10.1016/j.vaccine.2010.09.093. [DOI] [PubMed] [Google Scholar]
  53. Webster G J, Reignat S, Brown D, Ogg G S, Jones L, Seneviratne S L, Williams R, Dusheiko G, Bertoletti A. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol. 2004;78:5707–5719. doi: 10.1128/JVI.78.11.5707-5719.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Wen Y M, Wu X H, Hu D C, Zhang Q P, Guo S Q. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet. 1995;345:1575–1576. doi: 10.1016/S0140-6736(95)91126-X. [DOI] [PubMed] [Google Scholar]
  55. Wu C, Shi H, Wang Y, Lu M, Xu Y, Chen X. A case of hepatitis B reactivation due to the hepatitis B virus escape mutant in a patient undergoing chemotherapy. Virol Sin. 2012;27:369–372. doi: 10.1007/s12250-012-3284-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Wu W, Shi Y, Li S, Zhang Y, Liu Y, Wu Y, Chen Z. Blockade of Tim-3 signaling restores the virus-specific CD8(+) T-cell response in patients with chronic hepatitis B. Eur J Immunol. 2012;42:1180–1191. doi: 10.1002/eji.201141852. [DOI] [PubMed] [Google Scholar]
  57. Xu D Z, Zhao K, Guo L M, Li L J, Xie Q, Ren H, Zhang J M, Xu M, Wang H F, Huang W X, Bai X F, Niu J Q, Liu P, Chen X Y, Shen X L, Yuan Z H, Wang X Y, Wen Y M. A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PloS One. 2008;3:e2565. doi: 10.1371/journal.pone.0002565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Xu D Z, Wang X Y, Shen X L, Gong G Z, Ren H, Guo L M, Sun A M, Xu M, Li L J, Guo X H, Zhen Z, Wang H F, Gong H Y, Xu C, Jiang N, Pan C, Gong Z J, Zhang J M, Shang J, Xu J, Xie Q, Wu T F, Huang W X, Li Y G, Yuan Z H, Wang B, Zhao K, Wen Y M. Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol. 2013;59:450–456. doi: 10.1016/j.jhep.2013.05.003. [DOI] [PubMed] [Google Scholar]
  59. Yalcin K, Acar M, Degertekin H. Specific hepatitis B vaccine therapy in inactive HBsAg carriers: a randomized controlled trial. Infection. 2003;31:221–225. doi: 10.1007/s15010-003-3187-1. [DOI] [PubMed] [Google Scholar]
  60. Yang P L, Althage A, Chung J, Maier H, Wieland S, Isogawa M, Chisari F V. Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A. 2010;107:798–802. doi: 10.1073/pnas.0913498107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Yao X, Zheng B, Zhou J, Xu D Z, Zhao K, Sun S H, Yuan Z H, Wen Y M. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine. 2007;25:1771–1779. doi: 10.1016/j.vaccine.2006.11.019. [DOI] [PubMed] [Google Scholar]
  62. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009;137:1593–1608. doi: 10.1053/j.gastro.2009.08.063. [DOI] [PubMed] [Google Scholar]

Articles from Virologica Sinica are provided here courtesy of Wuhan Institute of Virology, Chinese Academy of Sciences

RESOURCES